ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 173 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,687 | +53.3% | 285,000 | +46.2% | 17.16% | +36.8% |
| Q2 2023 | $17,404 | +64.7% | 195,000 | +97.8% | 12.55% | +69.6% |
| Q1 2023 | $10,569 | -42.8% | 98,571 | -34.9% | 7.40% | -17.4% |
| Q4 2022 | $18,492 | -99.9% | 151,409 | +4.3% | 8.95% | -22.1% |
| Q3 2022 | $16,699,000 | +49.7% | 145,209 | +21.0% | 11.49% | +32.8% |
| Q2 2022 | $11,155,000 | -40.8% | 120,000 | -25.2% | 8.65% | -25.0% |
| Q1 2022 | $18,836,000 | +20.8% | 160,500 | +38.5% | 11.54% | +222.7% |
| Q4 2021 | $15,590,000 | +46.6% | 115,885 | +73.7% | 3.58% | -59.6% |
| Q3 2021 | $10,634,000 | +62.6% | 66,714 | +34.2% | 8.85% | +93.7% |
| Q2 2021 | $6,541,000 | +87.5% | 49,721 | +83.7% | 4.57% | +415.7% |
| Q1 2021 | $3,488,000 | -9.8% | 27,064 | +16.7% | 0.89% | -67.5% |
| Q4 2020 | $3,866,000 | – | 23,183 | – | 2.72% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |